Literature DB >> 17128426

Assessment of futility in clinical trials.

Steven Snapinn1, Mon-Gy Chen, Qi Jiang, Tony Koutsoukos.   

Abstract

The term 'futility' is used to refer to the inability of a clinical trial to achieve its objectives. In particular, stopping a clinical trial when the interim results suggest that it is unlikely to achieve statistical significance can save resources that could be used on more promising research. There are various approaches that have been proposed to assess futility, including stochastic curtailment, predictive power, predictive probability, and group sequential methods. In this paper, we describe and contrast these approaches, and discuss several issues associated with futility analyses, such as ethical considerations, whether or not type I error can or should be reclaimed, one-sided vs two-sided futility rules, and the impact of futility analyses on power.

Mesh:

Year:  2006        PMID: 17128426     DOI: 10.1002/pst.216

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  22 in total

Review 1.  Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

Authors:  Toshimitsu Hamasaki; Scott R Evans; Koko Asakura
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

2.  To stop or not to stop: a value of information view.

Authors:  Uwe Siebert; Lára R Hallsson
Journal:  Eur J Epidemiol       Date:  2018-08-17       Impact factor: 8.082

3.  Application of futility analysis to refine jitter recordings in myasthenia gravis.

Authors:  Pushpa Narayanaswami; Norberto Pantoja-Galicia; Rebecca A Betensky; Seward B Rutkove
Journal:  Muscle Nerve       Date:  2012-04       Impact factor: 3.217

Review 4.  Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making.

Authors:  Thomas M Caparrotta; James W Dear; Helen M Colhoun; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2019-07-24       Impact factor: 4.335

5.  Comparison of futility monitoring guidelines using completed phase III oncology trials.

Authors:  Qiang Zhang; Boris Freidlin; Edward L Korn; Susan Halabi; Sumithra Mandrekar; James J Dignam
Journal:  Clin Trials       Date:  2016-09-22       Impact factor: 2.486

6.  Superiority of combining two independent trials in interim futility analysis.

Authors:  Qiqi Deng; Ying-Ying Zhang; Dooti Roy; Ming-Hui Chen
Journal:  Stat Methods Med Res       Date:  2019-04-08       Impact factor: 3.021

7.  A Mixed-Methods Cluster-Randomized Controlled Trial of a Hospital-Based Psychosocial Stimulation and Counseling Program for Caregivers and Children with Severe Acute Malnutrition.

Authors:  Allison I Daniel; Mike Bwanali; Josephine Chimoyo Tenthani; Melissa Gladstone; Wieger Voskuijl; Isabel Potani; Frank Ziwoya; Kate Chidzalo; Emmie Mbale; Anna Heath; Celine Bourdon; Jenala Njirammadzi; Meta van den Heuvel; Robert H J Bandsma
Journal:  Curr Dev Nutr       Date:  2021-07-21

8.  Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biom J       Date:  2016-10-19       Impact factor: 2.207

9.  Futility stopping in clinical trials, optimality and practical considerations.

Authors:  Yen Chang; Tianhao Song; Jane Monaco; Anastasia Ivanova
Journal:  J Biopharm Stat       Date:  2020-09-14       Impact factor: 1.051

10.  The role of the Data and Safety Monitoring Board in a clinical trial: the CRISIS study.

Authors:  Richard Holubkov; T Charles Casper; J Michael Dean; K J S Anand; Jerry Zimmerman; Kathleen L Meert; Christopher J L Newth; John Berger; Rick Harrison; Douglas F Willson; Carol Nicholson
Journal:  Pediatr Crit Care Med       Date:  2013-05       Impact factor: 3.624

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.